Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - What's Next?
Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped up from $69.00 to $73.31 prior to trading, with a trading volume of 130 shares. Analysts have upgraded the stock to a "strong-buy" rating, with five analysts rating it as such. The company reported $16.06 EPS, missing estimates, and had a revenue of $1.43 billion for the quarter. Zealand Pharma focuses on peptide-based medicines for gastrointestinal and metabolic diseases. Despite a strong buy rating, it is not among the top recommended stocks by analysts.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $69.00, but opened at $73.31. Zealand Pharma A/S shares last traded at $73.31, with a volume of 130 shares.
Get Zealand Pharma A/S alerts:
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. BNP Paribas upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Zacks Research upgraded shares of Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Five investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Strong Buy".
Get Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Trading Up 6.2%
The firm has a market capitalization of $5.21 billion, a PE ratio of 5.15 and a beta of 0.73. The firm's fifty day moving average is $60.71 and its two-hundred day moving average is $65.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%.The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. On average, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.
Zealand Pharma A/S Company Profile
(Get Free Report)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories
- Five stocks we like better than Zealand Pharma A/S
- How to Calculate Stock Profit
- Can Advantage2 Help Overcome D-Wave's Share Price Plateau?
- What Are Dividends? Buy the Best Dividend Stocks
- Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything
- How to buy stock: A step-by-step guide for beginners
- The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Zealand Pharma A/S Right Now?
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
